Last reviewed · How we verify
NCT06957626
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
trial in Colorectal Polyp in 150 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 25 April 2023 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Conditions studied
- Colorectal Polyp — all drugs for Colorectal Polyp →
- Colorectal Cancer Recurrent — all drugs for Colorectal Cancer Recurrent →
- Colorectal Adenoma — all drugs for Colorectal Adenoma →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 40 to 75, any sex, with Colorectal Polyp or Colorectal Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The characteristics of the intestinal microbiota in high-risk colorectal polyp recurrence and their relationship with disease pathogenesis have not yet been fully elucidated. This study aims to analyze the microbial community characteristics in the intestinal mucosal tissue of patients after polypectomy with recurrence of colorectal polyps. Additionally, this research holds significant importance for understanding the etiology of adenoma recurrence and develop a microbiota and metabolite-based predicting tool.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06957626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Polyp
Currently open trials in the same condition.
- NCT06791408 — Clinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps · recruiting
- NCT06715384 — Evaluation of a CAM System for Colorectal Polyp Size Measurement · NA · recruiting
- NCT06193356 — Detection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable · NA · recruiting
- NCT06502704 — Bile Acids and Microbiome in Early Colorectal Carcinogenesis · recruiting
- NCT06447012 — Artificial Intelligence Development for Colorectal Polyp Diagnosis · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06957626 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06957626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing